A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma.
We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when free kappa light chains were noticeably reduced in the serum. After discontinuation of bortezomib, liver enzymes recovered gradually to baseline. Then, the patient was started on a thalidomide-containing regimen, which he was able to tolerate well. The patient achieved complete remission prior to autologous stem cell transplantation (ASCT). The patient underwent ASCT without occurrence of further liver toxicity.
Division of Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea.
Youngwoon
Y
Kim
Ka Young
KY
Kim
Su Hyun
SH
Lee
Yoon Yung
YY
Chung
Seung-Ah
SA
Yahng
Sung-Eun
SE
Lee
Gyeongsin
G
Park
Chang-Ki
CK
Min